Vedanta Biosciences, Inc news

• Full Phase 1 data analysis of VE303, a defined bacterial consortium candidate for C. difficile infection, published in Cell Host & Microbe
• Positive topline Phase 2 results for VE303 announced in 2021; Phase 3 preparations underway
• Acceptance of three abstracts for podium presentations at Digestive Disease Week 2022

Vedan

Vedanta Biosciences, a clinical-stage company that is developing a potential new category of oral therapies based on defined bacterial consortia, today announced the appointment of Simona Levi, Ph.D., J.D., as Chief Legal Officer and Corporate Secretary. Dr. Levi brings over 25 years of United States and international legal experience with private and public companies across the life sciences industry focusing on complex transactions, intellectual pro

• Proceeds expected to be used primarily to support a Phase 3 trial of lead candidate VE303 in Clostridioides difficile infection (CDI) and a Phase 2 trial of VE202 in inflammatory bowel disease (IBD)
• Topline data from Phase 2 trial of VE303 in CDI are anticipated in Q3 2021
• Plans to initiate Phase 2 trial of VE202 for treatment of mild to moderate ulcerative colitis in H2 2021

Vedanta Bi